- Home
- MIRM vs NOV Comparison
MIRM vs NOV Comparison
Compare MIRM & NOV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MIRM | NOV |
|---|---|---|
| Founded | 2018 | 1862 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Metal Fabrications |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 6.6B |
| IPO Year | 2019 | 1996 |
Fundamental Metrics
Financial Performance| Metric | MIRM | NOV |
|---|---|---|
| Price | $106.24 | $20.64 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 13 | 15 |
| Target Price | ★ $119.85 | $19.47 |
| AVG Volume (30 Days) | 667.9K | ★ 4.8M |
| Earning Date | 05-06-2026 | 04-27-2026 |
| Dividend Yield | N/A | ★ 1.73% |
| EPS Growth | ★ 74.59 | N/A |
| EPS | N/A | ★ 0.05 |
| Revenue | $19,138,000.00 | ★ $8,744,000,000.00 |
| Revenue This Year | $26.22 | N/A |
| Revenue Next Year | $22.04 | $3.81 |
| P/E Ratio | ★ N/A | $395.80 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $42.89 | $11.65 |
| 52 Week High | $112.00 | $20.93 |
Technical Indicators
Market Signals| Indicator | MIRM | NOV |
|---|---|---|
| Relative Strength Index (RSI) | 62.25 | 59.23 |
| Support Level | $87.26 | $17.96 |
| Resistance Level | $107.51 | N/A |
| Average True Range (ATR) | 5.87 | 0.55 |
| MACD | 0.98 | -0.03 |
| Stochastic Oscillator | 75.13 | 84.92 |
Price Performance
Historical ComparisonAbout MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.
About NOV NOV Inc.
NOV designs, manufactures, and sells a wide range of equipment and components supplying the oil and gas industry, including rig equipment, downhole tools, drill pipe, and well casing. NOV's customers include major integrated oil companies, national oil companies, independent oil and gas companies, and drilling contractors. Its operations are organized into two reportable segments: energy products and services and energy equipment. NOV operates on a global scale, with international markets contributing nearly two-thirds of its annual revenue.